Page 81 - AN-3-1

Advanced Neurology COVID-19 and neurodegenerative diseases

39. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, 51. Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A.
Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. Hyperinflammation and fibrosis in severe COVID-19
2015;1:15056. patients: Galectin-3, a target molecule to consider. Front
doi: 10.1038/NRDP.2015.56 Immunol. 2020;11:2069.
40. Armstrong RA. Risk factors for Alzheimer’s disease. Folia doi: 10.3389/FIMMU.2020.02069
Neuropathol. 2019;57(2):87-105. 52. Wang X, Zhang S, Lin F, Chu W, Yue S. Elevated galectin-3
doi: 10.5114/FN.2019.85929 levels in the serum of patients with Alzheimer’s disease. Am
J Alzheimers Dis Other Demen. 2015;30(8):729-732.
41. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s
disease: Pathogenesis, diagnostics, and therapeutics. Int J doi: 10.1177/1533317513495107
Nanomedicine. 2019;14:5541-5554. 53. N Hwang JM, Kim JH, Park JS, Chang MC, Park D.
Neurological diseases as mortality predictive factors for
doi: 10.2147/IJN.S200490
patients with COVID-19: A retrospective cohort study.
42. McQuaid C, Brady M, Deane R. SARS-CoV-2: Is there Neurol Sci. 2020;41(9):2317-2324.
neuroinvasion? Fluids Barriers CNS. 2021;18(1):32.
doi: 10.1007/S10072-020-04541-Z
doi: 10.1186/S12987-021-00267-Y
54. Li J, Long X, Huang H, et al. Resilience of Alzheimer’s
43. Matias-Guiu JA, Pytel V, Matias-Guiu J. Death rate due disease to COVID-19. J Alzheimers Dis. 2020;77(1):67-73.
to COVID-19 in Alzheimer’s disease and frontotemporal
dementia. J Alzheimers Dis. 2020;78(2):537-541. doi: 10.3233/JAD-200649
doi: 10.3233/JAD-200940 55. Vaz M, Silvestre S. Alzheimer’s disease: Recent treatment
strategies. Eur J Pharmacol. 2020;887:173554.
44. Zhou Y, Xu J, Hou Y, et al. Network medicine links
SARS-CoV-2/COVID-19 infection to brain microvascular doi: 10.1016/J.EJPHAR.2020.173554
injury and neuroinflammation in dementia-like cognitive 56. Gowayed MA, Refaat R, Ahmed WM, El-Abhar HS. Effect
impairment. Alzheimers Res Ther. 2021;13(1):110. of galantamine on adjuvant-induced arthritis in rats. Eur J
doi: 10.1186/s13195-021-00850-3 Pharmacol. 2015;764:547-553.
45. Gao YD, Ding M, Dong X, et al. Risk factors for severe doi: 10.1016/J.EJPHAR.2015.07.038
and critically ill COVID-19 patients: A review. Allergy. 57. Gil R, Arroyo-Anlló EM. Alzheimer’s disease and face masks
2021;76(2):428-455. in times of COVID-19. J Alzheimers Dis. 2021;79(1):9-14.
doi: 10.1111/ALL.14657 doi: 10.3233/JAD-201233
46. Lim KH, Yang S, Kim SH, Joo JY. Elevation of ACE2 as a 58. Kobayashi R, Hayashi H, Kawakatsu S, et al. Recognition
SARS-CoV-2 entry receptor gene expression in Alzheimer’s of the coronavirus disease 2019 pandemic and face
disease. J Infect. 2020;81(3):e33-e34. mask wearing in patients with Alzheimer’s disease: An
doi: 10.1016/J.JINF.2020.06.072 investigation at a medical centre for dementia in Japan.
Psychogeriatrics. 2020;20(6):923-925.
47. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s
disease: Current evidence and future directions. Alzheimers doi: 10.1111/psyg.12617
Dement. 2016;12(6):719-732. 59. Gan J, Liu S, Wu H, et al. The impact of the COVID-19
doi: 10.1016/J.JALZ.2016.02.010 pandemic on Alzheimer’s disease and other dementias.
Front Psychiatry. 2021;12:703481.
48. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA.
The role of IL-6 and other mediators in the cytokine storm doi: 10.3389/fpsyt.2021.703481
associated with SARS-CoV-2 infection. J Allergy Clin 60. El Haj M, Altintas E, Chapelet G, Kapogiannis D, Gallouj K.
Immunol. 2020;146(3):518-534.e1. High depression and anxiety in people with Alzheimer’s
doi: 10.1016/J.JACI.2020.07.001 disease living in retirement homes during the covid-19
crisis. Psychiatry Res. 2020;291:113294.
49. Rahman MA, Islam K, Rahman S, Alamin M.
Neurobiochemical cross-talk between COVID-19 and doi: 10.1016/J.PSYCHRES.2020.113294
Alzheimer’s disease. Mol Neurobiol. 2020;58(3):1017-1023. 61. Boutoleau-Bretonnière C, Pouclet-Courtemanche H, Gillet A,
doi: 10.1007/S12035-020-02177-W et al. Impact of confinement on the burden of caregivers
of patients with the behavioral variant of frontotemporal
50. Ciaccio M, Lo Sasso B, Scazzone C, et al. COVID-19 and dementia and Alzheimer disease during the COVID-19
Alzheimer’s disease. Brain Sci. 2021;11(3):305.
crisis in France. Dement Geriatr Cogn Dis Extra. 2020;10(3):
doi: 10.3390/BRAINSCI11030305 127-134.

Volume 3 Issue 1 (2024) 10 https://doi.org/10.36922/an.2200